{"id":47079,"date":"2025-11-12T22:44:17","date_gmt":"2025-11-12T14:44:17","guid":{"rendered":"https:\/\/flcube.com\/?p=47079"},"modified":"2025-11-12T22:44:27","modified_gmt":"2025-11-12T14:44:27","slug":"gempharmatech-memorial-sloan-kettering-and-neomab-platform-accelerate-discovery-of-fully-human-therapeutic-antibodies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=47079","title":{"rendered":"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies"},"content":{"rendered":"\n<p><strong>GemPharmatech Inc.<\/strong>, (<a href=\"https:\/\/www.google.com\/finance\/quote\/688046:SHA\">SHA: 688046<\/a>) a global leader in pre\u2011clinical research solutions and genetically\u2011engineered mouse models, today announced a non\u2011exclusive collaboration with the <strong>Memorial Sloan Kettering Cancer Center (MSKCC)<\/strong>. The partnership unlocks GemPharmatech\u2019s <strong>NeoMab<\/strong> platform\u2014an advanced transgenic mouse system\u2014enabling MSKCC scientists to expedite the discovery of fully human therapeutic antibodies against high\u2011value oncology targets.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-collaboration-key-points\">Collaboration Key Points<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partnering Organizations<\/strong><\/td><td>GemPharmatech &amp; MSKCC<\/td><\/tr><tr><td><strong>Platform Leveraged<\/strong><\/td><td>NeoMab \u2013 next\u2011generation transgenic mice for rapid antibody discovery<\/td><\/tr><tr><td><strong>Objective<\/strong><\/td><td>Accelerate development of fully human therapeutic antibodies for unmet cancer indications<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>MSKCC researchers gain access to GemPharmatech\u2019s full spectrum of pre\u2011clinical services and resources<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-why-neomab-matters\">Why NeoMab Matters<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Speed &amp; Precision<\/strong> \u2013 NeoMab mice are engineered for efficient human antibody generation, shortening lead\u2011time from target to candidate.<\/li>\n\n\n\n<li><strong>Clinical Relevance<\/strong> \u2013 The platform delivers fully human molecules, reducing immunogenicity risks in human trials.<\/li>\n\n\n\n<li><strong>Strategic Alignment<\/strong> \u2013 MSKCC\u2019s extensive pre\u2011clinical infrastructure now combines with GemPharmatech\u2019s unique biology, creating a powerful pipeline for high\u2011impact oncology therapies.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that are subject to risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GemPharmatech Inc., (SHA: 688046) a global leader in pre\u2011clinical research solutions and genetically\u2011engineered mouse models,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":47083,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,9],"tags":[30,2215,4456],"class_list":["post-47079","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-hospital","tag-biotech","tag-gempharmatech","tag-sha-688046"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GemPharmatech Inc., (SHA: 688046) a global leader in pre\u2011clinical research solutions and genetically\u2011engineered mouse models, today announced a non\u2011exclusive collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC). The partnership unlocks GemPharmatech\u2019s NeoMab platform\u2014an advanced transgenic mouse system\u2014enabling MSKCC scientists to expedite the discovery of fully human therapeutic antibodies against high\u2011value oncology targets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=47079\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies\" \/>\n<meta property=\"og:description\" content=\"GemPharmatech Inc., (SHA: 688046) a global leader in pre\u2011clinical research solutions and genetically\u2011engineered mouse models, today announced a non\u2011exclusive collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC). The partnership unlocks GemPharmatech\u2019s NeoMab platform\u2014an advanced transgenic mouse system\u2014enabling MSKCC scientists to expedite the discovery of fully human therapeutic antibodies against high\u2011value oncology targets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=47079\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T14:44:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-12T14:44:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1205-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47079#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47079\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies\",\"datePublished\":\"2025-11-12T14:44:17+00:00\",\"dateModified\":\"2025-11-12T14:44:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47079\"},\"wordCount\":207,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47079#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1205-1.webp\",\"keywords\":[\"Biotech\",\"GemPharmatech\",\"SHA: 688046\"],\"articleSection\":[\"Company\",\"Deals\",\"Hospital\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47079#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47079\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=47079\",\"name\":\"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47079#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47079#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1205-1.webp\",\"datePublished\":\"2025-11-12T14:44:17+00:00\",\"dateModified\":\"2025-11-12T14:44:27+00:00\",\"description\":\"GemPharmatech Inc., (SHA: 688046) a global leader in pre\u2011clinical research solutions and genetically\u2011engineered mouse models, today announced a non\u2011exclusive collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC). The partnership unlocks GemPharmatech\u2019s NeoMab platform\u2014an advanced transgenic mouse system\u2014enabling MSKCC scientists to expedite the discovery of fully human therapeutic antibodies against high\u2011value oncology targets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47079#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47079\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47079#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1205-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1205-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47079#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies - Insight, China&#039;s Pharmaceutical Industry","description":"GemPharmatech Inc., (SHA: 688046) a global leader in pre\u2011clinical research solutions and genetically\u2011engineered mouse models, today announced a non\u2011exclusive collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC). The partnership unlocks GemPharmatech\u2019s NeoMab platform\u2014an advanced transgenic mouse system\u2014enabling MSKCC scientists to expedite the discovery of fully human therapeutic antibodies against high\u2011value oncology targets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=47079","og_locale":"en_US","og_type":"article","og_title":"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies","og_description":"GemPharmatech Inc., (SHA: 688046) a global leader in pre\u2011clinical research solutions and genetically\u2011engineered mouse models, today announced a non\u2011exclusive collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC). The partnership unlocks GemPharmatech\u2019s NeoMab platform\u2014an advanced transgenic mouse system\u2014enabling MSKCC scientists to expedite the discovery of fully human therapeutic antibodies against high\u2011value oncology targets.","og_url":"https:\/\/flcube.com\/?p=47079","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-12T14:44:17+00:00","article_modified_time":"2025-11-12T14:44:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1205-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=47079#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=47079"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies","datePublished":"2025-11-12T14:44:17+00:00","dateModified":"2025-11-12T14:44:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=47079"},"wordCount":207,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=47079#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1205-1.webp","keywords":["Biotech","GemPharmatech","SHA: 688046"],"articleSection":["Company","Deals","Hospital"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=47079#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=47079","url":"https:\/\/flcube.com\/?p=47079","name":"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=47079#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=47079#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1205-1.webp","datePublished":"2025-11-12T14:44:17+00:00","dateModified":"2025-11-12T14:44:27+00:00","description":"GemPharmatech Inc., (SHA: 688046) a global leader in pre\u2011clinical research solutions and genetically\u2011engineered mouse models, today announced a non\u2011exclusive collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC). The partnership unlocks GemPharmatech\u2019s NeoMab platform\u2014an advanced transgenic mouse system\u2014enabling MSKCC scientists to expedite the discovery of fully human therapeutic antibodies against high\u2011value oncology targets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=47079#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=47079"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=47079#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1205-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1205-1.webp","width":1080,"height":608,"caption":"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=47079#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1205-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47079"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47079\/revisions"}],"predecessor-version":[{"id":47084,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47079\/revisions\/47084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/47083"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}